Steven Nathan, MD
Enriched profileMedical Director, Advanced Lung Disease and Lung Transplant Program (Schar Chair, Advanced Lung Disease and Lung Transplant) · Inova Fairfax Hospital
Steven Nathan is Medical Director, Advanced Lung Disease and Lung Transplant Program (Schar Chair, Advanced Lung Disease and Lung Transplant) at Inova Fairfax Hospital. OpenAlex indexes 603 publications with 24,602 citations (h-index 75); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Pulmonary Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Steven D. Nathan, MD, is Medical Director, Advanced Lung Disease and Lung Transplant Program (Schar Chair, Advanced Lung Disease and Lung Transplant) at Inova Fairfax Hospital (Inova Schar Heart and Vascular / Inova Medical Group - Transplant Specialties). The public record shows 603 publications with 24,602 citations (h-index 75), centered on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension Research and Treatments, Transplantation: Methods and Outcomes. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 50 companies.
- Most recent indexed publication: 2026 · The European respiratory journal
- Top research focus: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 50 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 31 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 236.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- Chair
FDA Anesthesiology and Respiratory Therapy Devices Panel (advisory committee service on FDA panels/steering committees for IPF and pulmonary hypertension trials)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →inova.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Pulmonary Hypertension Association Registry
Sponsor: Pulmonary Hypertension Association, Inc.
- Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso
Sponsor: Inova Health Care Services
- The Six Minute Walk Test: Influence of Instruction on Results
Sponsor: Inova Health Care Services
Industry payments
Updated 27 Aug 2026
50 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202563 payments$113,280openpaymentsdata.cms.gov ↗
- United Therapeutics CorporationProgram year2025134 payments$104,656openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20255 payments$10,706openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
44.2%Kinase inhibitor36.1%Ofev100%Part D≥28 patientsPyridone8.2%Pirfenidone100%Part D<11 patientsCardiovascular
16.8%Endothelin Receptor Antagonist8.5%Opsumit75%Letairis26%Part D<11 patientsLoop diuretic3.8%Furosemide100%Part D<11 patientsMetabolism & gastrointestinal
13.6%Corticosteroid11.6%Prednisone100%Part D≥14 patientsProton pump inhibitor2%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
2 congress contributions (2017) across AMCP per OpenAlex. The most recent:
- Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis
AMCP Meeting
AMCP2017Co-author - Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension
AMCP Meeting
AMCP2017Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Vascular targeted therapies for fibrotic lung disease: start of a new era?
The European respiratory journal
Editorial2026 - Early post-transplant recipient tissue injury predicts allograft function, rejection and survival in lung transplant recipients: evidence from cell-free DNA.
The European respiratory journal
Article2026 - Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis.
The European respiratory journal
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/steven-nathan-1996066
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Steven-Nathan-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/InovaHealth/posts/inova-pulmonologist-dr-steven-nathan-is-heading-a-team-of-clinical-researchers-a/10157850613538393
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Fellowship
Pulmonary & Critical Care Medicine and Lung Transplantation, Cedars-Sinai Medical Center
1992verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →inova.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →inova.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗
- Board Certified: Pulmonary Disease
Critical Care Medicine, Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →inova.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗
Editorial & leadership roles
journal and society appointments- Medical Director
Advanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗ - Editorial board member
Thorax (BMJ journal)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →inova.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →inova.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine / Professor of Medical Education
University of Virginia, Inova Campus
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →inova.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →touchrespiratory.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
William Ershler, MD
Inova Fairfax Hospital
Hannah Donovan, MD
Inova Fairfax Hospital
Ramani Balu, MD
Inova Fairfax Hospital
Alan Speir, MD
Inova Fairfax Hospital